IRB Study Number 24-559
Status Recruiting
Institute Taussig Cancer Institute
Description
Primary Objective
To evaluate the long-term safety through 15 years post infusion of patients who received IP in a Caribou-sponsored study, an IIT or by special access program
Inclusion Criteria
Written informed consent (by patient or legal representative) obtained prior to study specific activities/enrollment.
Received Caribou CAR-T Cell Therapy IP and completed or discontinued early from a Caribou-sponsored study evaluating IP or was administered IP under a special access program or as part of an IIT.
Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 1 year post IP infusion.
Exclusion Criteria
Exclusion Criteria Not Available
